419. Allogenic CAR T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML)
نویسندگان
چکیده
منابع مشابه
Adoptive immunotherapy for AML with CD123-engager T cells
Background T cell immunotherapy is one promising approach to improve outcomes for patients with AML; however, infused T cells do not redirect resident T cells to tumors. To overcome this, we have genetically modified T cells to produce a secretable, bispecific T cell engager (ENG-T cells). Consistent synthesis of engagers by T cells should be superior to the direct infusion of the recombinant b...
متن کاملDETERMINATION OF A SHARED EPITOPE ON CELLS FROM ACUTE MYELOGENIC LEUKEMIA (AML) AND T-ACUTE LYMPHOBLASTIC LEUKEMIA ( T-ALL)
Two IgM monoclonal antibodies (MAb) with strong reactivity for granulocytes and to a lesser extent for lurkat cell lines were established by immunizing BALBI c mice with a histiocytic cell line (UY37). These two MAbs (designated as 6C9 and 4C4) reacted with blast cells of T-acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML) patients as well as leukemic cells from pat...
متن کاملImmunotherapy of acute myeloid leukemia based on γδ T cells
A current major challenge of acute myeloid leukemia research is to develop immunotherapeutic strategies that would be employable in all patients. We recently reported that appropriately stimulated γδ T cells are fully capable of mediating cytotoxicity against leukemic blasts.
متن کاملTargeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the treatment of hematologic malignancies. Here we describe our preclinical work with a dual-affinity retargeting (DART) molecule generated from antibodies to CD3 and CD123, designed to redirect T cells against acute myeloid leukemia blasts. The CD3×CD123 DART (also referred to as MGD006/S80880) consi...
متن کاملT-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Therapy
سال: 2015
ISSN: 1525-0016
DOI: 10.1016/s1525-0016(16)34028-x